December 22, 2025 | Abbott Park, Illinois — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the Volt™ Pulsed Field Ablation (PFA) System for the treatment of patients with atrial fibrillation (AFib). The approval enables Abbott to begin commercial use of its next-generation cardiac ablation system in the United States, following earlier CE Mark clearance in Europe, and marks a significant milestone in the evolution of minimally invasive electrophysiology technologies.
Science Significance
The Volt™ PFA System represents a scientific advancement in cardiac rhythm management, leveraging pulsed field ablation, a non-thermal technique that uses high-energy electrical pulses to selectively disrupt abnormal cardiac tissue while preserving surrounding structures. Unlike traditional thermal ablation methods, PFA is designed to be gentler on cardiac tissue, reducing collateral damage and supporting more precise lesion formation. Clinical evidence from the VOLT-AF IDE study, which enrolled 392 patients across 40 global centers, demonstrated clinically meaningful safety and effectiveness in both paroxysmal and persistent AFib, reinforcing the system’s role as a next-generation solution for complex arrhythmias.
Regulatory Significance
FDA approval of the Volt™ PFA System reflects rigorous regulatory evaluation of clinical performance, safety, and device quality systems. The decision was supported by robust multicenter trial data and aligns with Good Clinical Practice (GCP) standards governing investigational device studies. As a Class III medical device, Volt is subject to ongoing post-market surveillance, quality system regulation (QSR), and clinical follow-up, ensuring continued compliance throughout its commercial lifecycle. The approval also underscores the FDA’s increasing engagement with innovative non-thermal ablation technologies that address unmet needs in cardiovascular care.
Business Significance
Advertisement
From a business perspective, the approval strengthens Abbott’s leadership position in electrophysiology and cardiac ablation markets. The Volt™ system complements Abbott’s existing EP portfolio and integrates with the EnSite™ X mapping platform, enabling streamlined workflows and differentiated clinical value. With AFib prevalence rising and procedural volumes increasing globally, Volt positions Abbott to capture growing demand for safer, faster, and more efficient ablation technologies. The approval also supports Abbott’s broader strategy of expanding high-value MedTech solutions that deliver measurable clinical and operational benefits to healthcare systems.
Patients’ Significance
For patients, the FDA approval translates into expanded access to a minimally invasive treatment option that may offer shorter procedure times, faster recovery, and improved long-term outcomes. AFib affects millions of Americans and significantly increases the risk of stroke, heart failure, and mortality. The Volt™ PFA System’s ability to support conscious sedation instead of general anesthesia addresses a major barrier for some patients and may reduce procedural risk. By improving safety profiles and reducing the need for repeat ablations, the technology has the potential to enhance quality of life and disease management for people living with abnormal heart rhythms.
Policy Significance
The approval aligns with broader public health and regulatory priorities aimed at addressing the growing burden of cardiovascular disease through innovation and evidence-based technology adoption. As AFib prevalence is expected to rise substantially over the coming decades, regulatory support for next-generation, minimally invasive devices plays a key role in strengthening healthcare system resilience. The Volt™ approval also reflects policy efforts to encourage device innovation that improves outcomes while reducing procedural complexity and resource utilization, contributing to more sustainable cardiovascular care delivery.
The FDA approval of Abbott’s Volt™ Pulsed Field Ablation System marks a significant advancement in the treatment of atrial fibrillation, combining scientific innovation, clinical validation, and regulatory rigor. By introducing a next-generation, non-thermal ablation technology into routine clinical practice, Abbott reinforces the role of MedTech innovation under cGxP-aligned frameworks in improving patient safety and outcomes. As Volt enters commercial use in the United States and expands globally, it represents a meaningful step forward in the evolution of cardiac electrophysiology and regulated medical device innovation.
Source: Abbott press release
